PeptideGlobal

Once monthly semaglutide trials from Daewoong and Peptron win Korean approval on the same day

Daewoong with Tionlab and Peptron each won Korean approval on 19 November for Phase 1 trials of monthly semaglutide injections built on different depot technologies. The studies test safety and blood levels, not weight loss.

Illustration for the story: Once monthly semaglutide trials from Daewoong and Peptron win Korean approval on the same day

Illustration by Peptide Global, not a picture of the place in the story.

The short of itDaewoong with Tionlab and Peptron both won Korean approval on 19 November to start Phase 1 trials of monthly semaglutide injections.

Two Korean drug developers won approval on 19 November to start the first formal human trials of once monthly semaglutide, the GLP-1 medicine that patients now inject every week. Daewoong Pharmaceutical said it had cleared the Korean review for a Phase 1 study of TION-L002, built with Tionlab Therapeutics, and Peptron said the Ministry of Food and Drug Safety approved its own candidate, PT403. Both projects aim to turn a year of weekly shots into twelve. The approvals open testing in people; they do not show that a monthly version works.

Two Korean trial approvals on one day

Daewoong announced the clearance for TION-L002 on Thursday, according to Korea Biomedical Review. The candidate is a long acting injectable form of semaglutide, the molecule sold by Novo Nordisk as Ozempic and Wegovy. The partners want to stretch the interval between doses from one week to one month, which would cut the number of injections from 52 a year to 12. Their Phase 1 study is meant to check safety and pharmacokinetics, the way the drug is absorbed and cleared, and to compare the new formulation against a reference drug. The companies did not give the number of volunteers, the hospital or the start date, and they did not name the reference product in what they released on Thursday.

Peptron, listed on the KOSDAQ market, gave more detail on its own approval. The MFDS cleared an investigational new drug application for a Phase 1 trial of PT403, a monthly semaglutide injection made with the company's SmartDepot platform, the Seoul Economic Daily reported. According to that report, the study will enrol 22 healthy adults at Chungnam National University Hospital, and each person will get one injection under the skin. Peptron said it hopes to give the first dose next month, once the remaining start up steps are done. The trial is randomised, double blind and placebo controlled, and the amount given rises across three groups of volunteers. The two approvals arrived within hours of each other, and both put monthly dosing of an old molecule at the centre.

How the two depot technologies differ

The Daewoong project joins two delivery methods. Daewoong's CURE platform uses an inlet nozzle process to make drug particles of an even size, so that the medicine leaves the injection depot at a steady pace over a long period, the companies said. Tionlab's QujectSphere platform puts a coating on the surface of those particles to hold back the burst of drug that can come out soon after injection. Together the partners hope to keep early release low and the later release flat. Tionlab chief executive Lim Duk-soo said the goal is a monthly shot with efficacy comparable to existing treatments. Daewoong chief executive Park Sung-soo said Korean trial data would be used to widen global partnerships and speed up development.

Neither company has published human results from a formal trial yet, so the claims about smooth release over a month remain design goals that the Phase 1 data will test.

Peptron's SmartDepot is the company's own long acting injection platform, and PT403 applies it to semaglutide. A Peptron official said in the Seoul Economic Daily report that the approval matters because a monthly semaglutide product made at the company's own plant has entered full clinical development. In June the company presented early animal and pilot human data on PT403 to the annual meeting of the American Diabetes Association, and it plans to use the new study to shape later trials and build evidence for development abroad. Peptron did not restate the June figures with its announcement, and they are not repeated here. Neither company has published human results from a formal trial yet, so the claims about smooth release over a month remain design goals that the Phase 1 data will test.

What the Phase 1 studies will measure

The two first trials ask the same basic questions. Is a single monthly injection safe and tolerable, and does the drug level in the blood rise and fall in the shape the designers intended? For a depot product the answer depends on how much drug escapes in the first days and whether the rest follows evenly. Semaglutide's most common side effects in approved use are stomach and gut complaints such as nausea, so an early spike in drug levels is the risk developers try hardest to avoid. Peptron's design adds a safety review committee that must look at data from each group before the next and higher group is dosed. Daewoong's plan includes a head to head look at a reference drug.

ItemTION-L002PT403
DeveloperDaewoong Pharmaceutical with Tionlab TherapeuticsPeptron
Active moleculeSemaglutideSemaglutide
PlatformCURE particles with QujectSphere coatingSmartDepot
Approval announced19 November 202619 November 2026
Trial stagePhase 1Phase 1
Volunteers and siteNot disclosed22 healthy adults, Chungnam National University Hospital
DesignSafety, pharmacokinetics, comparison with a reference drugSingle dose, randomised, double blind, placebo controlled, three groups
Next stepSeek global co development partnersFirst dosing planned for December

None of the figures in the table describe effect on body weight or blood sugar, because Phase 1 studies in small groups are not built to show that. A monthly product would still need larger trials in people with obesity or diabetes before any regulator could weigh it, and neither company gave a timeline for those steps. The companies also gave no dose amounts, and none are added here. Healthy volunteers are often used in first studies of a new formulation because the aim is to learn how the drug behaves in the body. The question of whether once monthly semaglutide can match weekly injections on weight loss will only be answered in later, longer studies that the developers have not yet scheduled.

Why Korean drugmakers are working on semaglutide formats

Korean companies are attacking semaglutide from several sides as the market for obesity drugs grows. Daewon Pharmaceutical is testing a tablet, and this site reported that its oral semaglutide candidate DW5324 reached higher drug exposure than Rybelsus in two small studies. Korea United Pharm is preparing a Wegovy generic in Korea for a later launch. Daewoong itself is also developing DWRX5003, a semaglutide patch, with its affiliate Daewoong Therapeutics, according to Money Today. A monthly injection is a different bet: it keeps the injected form patients know but asks them to remember far fewer doses, which developers argue can help people stay on long treatment.

The first thing to watch is whether Peptron doses its first volunteer in December as planned, and when Daewoong names a site and start date. Pharmacokinetic results from these studies would show whether either depot holds drug levels steady over four weeks without a large early peak. The second is partnering. Both companies say the Korean data are meant to attract partners abroad, and a licensing deal would show how much value larger drugmakers see in once monthly semaglutide. The third is competition at home, where Hanmi's weight loss trial has already produced late stage data for its own GLP-1 drug. No company has said when a monthly product could reach patients, and no forecast is made here.

Conclusion

Daewoong with Tionlab and Peptron both won Korean approval on 19 November to start Phase 1 trials of once monthly semaglutide, using different depot technologies to slow the release of a drug now injected weekly. The studies will test safety and blood levels in small groups, with Peptron planning first dosing in December. Effect on weight is not part of these trials, and later studies, partners and timelines remain open questions.

Why it matters in South Korea

Korean drugmakers are building their own versions of semaglutide in new formats as obesity drug demand grows at home. Monthly depots from two local firms would give them assets to license abroad rather than only copy the weekly product.

What to watch

Whether Peptron doses its first volunteer in December, when Daewoong names a site and start date, the first pharmacokinetic results, and any licensing deal with a larger partner.

Sources

  1. Korea Biomedical Review: Daewoong, Tionlab get Korean nod to test once-monthly semaglutide
  2. Seoul Economic Daily: Peptron wins approval for Phase 1 trial of monthly obesity drug
  3. Seoul Economic Daily: Daewoong, Tionlab begin Phase 1 trial of monthly obesity shot
  4. Money Today: TION-L002 enters Phase 1 clinical trials in South Korea

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.